Delirium. Sudden changes in patients’ behavioral and psychological conditions
Conditions
Interventions
Intervention 1: Cyproheptadine Tab (Amin Pharmaceutical Company, Isfahan, IRAN), 4mg TDS orally from admission time, as daily interval for 7 days. Incidence and severity of patients’ delirium will be
Prevention
Placebo
Cyproheptadine Tab (Amin Pharmaceutical Company, Isfahan, IRAN), 4mg TDS orally from admission time, as daily interval for 7 days. Incidence and severity of patients’ delirium will be assesses as dail
Placebo Tab (Amin Pharmaceutical Company, Isfahan, IRAN), 4mg TDS orally from admission time, as daily interval for 7 days. Incidence and severity of patients’ delirium will be assesses as daily int
Sponsors
Vice Chancellor for Research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Non-cardiac surgical patients who are admitted to ICU and are hospitalized in Intensive Care Unit (ICU) for at-least 7 days. Exclusion Criteria: Patients with history of neurological diseases, psychiatric disorders, cyproheptadine hypersensitivity, active GI bleeding, glaucoma, urinary retention and arrhythmia will be excluded from the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Delirium. Timepoint: At ICU admission and then daily for 7 days. Method of measurement: CAM-ICU Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of Delirium. Timepoint: At ICU admission and then daily for 7 days. Method of measurement: CAM-ICU Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed